The antimalarial ferroquine: from bench to clinic.

Journal article

Ferroquine (FQ, SSR97193) is currently the most advanced organo-metallic drug candidate and about to complete phase II clinical trials as a treatment for uncomplicated malaria. This ferrocene-containing compound is active against both chloroquine-susceptible and chloroquine-resistant Plasmodium falciparum and P. vivax strains and/or isolates. This article focuses on the discovery of FQ, its antimalarial activity, the hypothesis of its mode of action, the current absence of resistance in vitro and recent clinical trials.

Authors: Biot, C; Nosten, F; Fraisse, L; Ter-Minassian, D; Khalife, J

• Publication status: Published
• Journal: Parasite (Paris, France)
• Volume: 18
• Issue: 3
• Pages: 207-214
• Publication date: 2011-08-01
• DOI: 10.1051/parasite/2011183207
• EISSN: 1776-1042
• ISSN: 1252-607X
• Language: English
• Keywords: Drug Resistance; Clinical Trials, Phase II as Topic; Plasmodium falciparum; Aminoquinolines; Ferrous Compounds; Antimalarials; Humans; Chloroquine; Plasmodium vivax; Malaria, Vivax; Malaria, Falciparum; Animals